Immuneering Corp — Director's Dealing 2022

Jan 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2022-01-14

Reporting Person: HAUSMAN DIANA (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-14	Stock Option	$13	A	25200	Acquired	2032-01-13	Class A Common Stock (25200)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a three year period commencing on February 14, 2022, and will be fully vested and exercisable on January 14, 2025.